Who should avoid laser/RF (pregnancy, implants, recent surgery)?
Energy-based vaginal treatments (laser or radiofrequency) are generally not first-line for genitourinary syndrome of menopause (GSM). Avoid or delay if you are pregnant, have an active vaginal infection, unexplained bleeding, a recent pelvic procedure without clearance, or device-specific contraindications (e.g., certain pacemakers/implants for RF). A clinician should confirm diagnosis, rule out red flags and sequence care. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Who should avoid laser/RF (pregnancy, implants, recent surgery)? Energy-based vaginal treatments—fractional CO2/Er:YAG laser and radiofrequency (RF)—aim to warm tissue to stimulate a wound-heal/remodelling response. They may reduce friction and insertional pain for some people with genitourinary syndrome of menopause (GSM), but they are not first-line and are not suitable for everyone. Before considering them, it’s important to confirm the problem really is GSM (rather than infection or a vulval dermatosis), optimise non-hormonal foundations (scheduled vaginal moisturiser and a compatible lubricant), and—if symptoms still affect quality of life—discuss local vaginal oestrogen or vaginal DHEA. Only then do devices come into view for carefully selected situations.
Absolute reasons to avoid/deferral. Pregnancy (including if trying to conceive) and unexplained vaginal bleeding are typical exclusions. Defer with active infections (thrush/BV/UTI) or open ulcers until treated, and avoid during fever or systemic illness. Post-procedure healing matters: after recent pelvic or perineal surgery, you’ll need your surgeon’s clearance before any device is used internally or at the vestibule.
Device-specific cautions. RF treatments can be unsuitable with certain implanted electronic devices (e.g., some pacemakers/defibrillators) or metal implants in the treatment field; your device make/model must be checked against the RF system’s instructions. For lasers, eye protection and tissue protection protocols must be followed strictly; clinicians should use UKCA/CE-marked systems for the intended indication and have training in settings and aftercare. If you have pelvic mesh or metalwork, placement relative to the treatment field should be reviewed.
When to pause and reassess. Symptoms such as malodorous green/grey discharge, intense itching with thick white discharge, new ulcers or rapidly changing white plaques, visible blood in urine or new post-menopausal bleeding point away from straightforward GSM and require assessment before any device therapy. Similarly, if your main barrier is pelvic floor guarding (a protective tightening after painful experiences), you’re likely to do better starting with pelvic health physiotherapy and graded comfort-first exposure; devices cannot relax muscles.
Medical conditions and medicines. Poorly controlled diabetes or conditions affecting healing, anticoagulation (blood thinners), immunosuppression, or recent radiotherapy to the pelvis merit tailored advice and sometimes deferral. Sensitivity to topical anaesthetics or a history of keloid scarring should also be discussed. If you use condoms or toys, remember that some oil-based products degrade latex—choose a water-based (condom-friendly) or silicone-based (long-glide) lubricant during recovery.
Where to find reliable basics and safety expectations. Patient-friendly self-care for dryness is outlined by the NHS (see NHS: vaginal dryness), and device safety/oversight principles are set by the UK regulator for medical devices (see the MHRA medical devices pages). In clinic, we will also talk through informed consent, aftercare, and specific red flags that should prompt review.
Planning your pathway. If you’re a candidate after guideline-led steps, we usually suggest a small series (e.g., two to three sessions several weeks apart) with review points to confirm benefit. For a plain-English overview of the concerns we assess and how treatment steps are sequenced, see our internal guides. That way you can see exactly where devices fit alongside moisturisers, local hormones, pelvic floor rehabilitation and psychosexual support.
Clinical Context
Who should avoid or delay right now? Anyone who is pregnant or trying to conceive; those with active BV/thrush/UTI, fever or systemic illness; people with unexplained bleeding, new ulcers or rapidly changing white plaques; and anyone healing from recent pelvic/perineal surgery without surgeon clearance. If you have certain pacemakers/defibrillators, metal implants in the treatment field, or pelvic mesh, device-specific cautions apply—bring exact make/model details to your consultation.
Who may be a candidate after foundations? People with GSM whose symptoms persist despite a scheduled vaginal moisturiser (many prefer hyaluronic-acid gels), a compatible personal lubricant (water-based for versatility; silicone-based for long glide; oil-based feels rich but may degrade latex), and—where acceptable—local vaginal oestrogen or vaginal DHEA. If entrance-focused burning continues despite good hydration and placement, and pelvic floor guarding has been addressed, a device pathway may be discussed.
Next steps & expectations. Set review points 6–12 weeks after each step. If progress stalls, reconsider the diagnosis (e.g., lichen sclerosus, vestibulodynia), check product placement (is the vestibule being treated?) and tackle co-drivers (tight kit, cycling pressure, fragranced products). Aim for the lowest effective maintenance once comfortable.
Evidence-Based Approaches
UK guidance prioritises a stepped pathway. The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; these options directly address low-oestrogen tissue biology and are typically used before devices. The NHS provides plain-English self-care and red-flag advice for vaginal dryness.
On device safety/oversight, UK expectations for intended use, vigilance and reporting are set out by the MHRA. As comparators with stronger evidence, Cochrane syntheses show local vaginal oestrogens improve dryness, soreness, dyspareunia and pH versus placebo across creams, tablets/pessaries and rings (see the Cochrane Library).
Peer-reviewed reviews indexed on PubMed discuss energy devices (laser/RF) for GSM, highlighting mixed study quality and heterogeneity, hence their non-first-line position in UK pathways. In practice, that means confirming diagnosis, optimising foundations and local therapy, and reserving devices for those who are appropriate candidates after shared decision-making and consent.